SeeAlconScience Profile Banner
Alcon Science Profile
Alcon Science

@SeeAlconScience

Followers
1K
Following
12
Media
343
Statuses
439

Learn about the science behind innovations from Alcon. This channel is intended for US Based HCPs only. See our community guidelines: https://t.co/OhMFHMoUKa

Joined March 2023
Don't wanna be here? Send us removal request.
@SeeAlconScience
Alcon Science
11 days
From promising new #DryEye and #Glaucoma medications to anti-inflammatory and allergy treatments, catch up on pharmaceutical innovations from #Alcon here: #AlconScience #MedicalAffairs #Ophthalmology #Optometry
Tweet media one
1
2
5
@SeeAlconScience
Alcon Science
3 days
Thanks to advancements in phacoemulsification technology, surgeons can preset intraocular pressure (IOP) settings to be maintained throughout #CataractSurgery. This video by #Alcon summarizes a study evaluating the impact of operating at physiologic vs high IOP.
0
1
3
@SeeAlconScience
Alcon Science
3 days
This clip summarizes results from a study of the impact of maintaining a high intraocular pressure (IOP) vs a near-physiologic IOP during #CataractSurgery. See the full video from #Alcon Global Medical Affairs here: #Ophthalmology #AlconInnovation
0
2
3
@SeeAlconScience
Alcon Science
4 days
Clareon® PanOptix® intraocular lenses feature a trifocal lens design with a hydrophobic acrylic material developed to improve optical clarity. Dr. Lillie Mosaddegh highlights outcomes from a study of 31 patients who received them in this video:
0
1
2
@SeeAlconScience
Alcon Science
4 days
#DryEyeDisease (DED) impacts approximately 38 million Americans. This figure underscores the substantial unmet need and the importance of innovative therapies to better manage this widespread condition. Visit to learn more. #AlconScience #MedicalAffairs
Tweet media one
1
1
4
@SeeAlconScience
Alcon Science
5 days
#Glaucoma and ocular hypertension treatment study: Watch this video from #Alcon Global Medical Affairs to see how intraocular pressure (IOP)-lowering Rho-kinase inhibitor netarsudil performs under real-world treatment conditions: #Ophthalmology
Tweet media one
0
1
3
@SeeAlconScience
Alcon Science
9 days
In this clinical trial, 27 subjects underwent bilateral #CataractSurgery using the Centurion® Vision System with ACTIVE SENTRY®, maintaining one eye at ≤28 mmHg intraocular pressure (IOP) and the other at ≥55-60 mmHg. See the results below. #AlconInnovation #Ophthalmology
0
1
4
@SeeAlconScience
Alcon Science
10 days
The clip below summarizes results from a study of the safety and efficacy of Rho-kinase inhibitor RHOPRESSA® for lowering intraocular pressure in patients with #glaucoma or ocular hypertension. See the full video from #Alcon Global Medical Affairs here:
0
2
3
@SeeAlconScience
Alcon Science
11 days
How does maintaining a higher intraocular pressure (IOP) vs a near-physiologic IOP during #CataractSurgery affect surgical efficiency and ocular tissue? Find out in this study summary video from #Alcon Global Medical Affairs: . #Ophthalmology
0
1
4
@SeeAlconScience
Alcon Science
12 days
As part of Alcon’s commitment to delivering innovative products to patients worldwide, we support independent clinical research via our Investigator-Initiated Trial (IIT) Program. Explore our areas of interest here: . #AlconScience #MedicalAffairs
Tweet media one
0
1
3
@SeeAlconScience
Alcon Science
12 days
Click through to watch the latest clinical research summary highlight Dr. Lillie Mosaddegh’s recent study on the visual outcomes and patient satisfaction with a trifocal IOL with advanced hydrophobic acrylic biomaterial. See more: #CataractSurgery #Alcon
0
1
2
@SeeAlconScience
Alcon Science
16 days
In a study utilizing an active-fluidics phacoemulsification system to sustain either high intraocular pressure (IOP) or near physiological IOP during cataract surgery, it was found that maintaining a lower IOP led to reduced trauma to ocular tissues.
0
1
3
@SeeAlconScience
Alcon Science
17 days
Dr. Lillie Mosaddegh highlights corrected and uncorrected visual acuities, refractive outcomes and patient-reported satisfaction after bilateral implantation of Clareon® PanOptix® intraocular lenses. See the full video: #CataractSurgery #AlconInnovation
0
1
3
@SeeAlconScience
Alcon Science
17 days
In recent phase 3 clinical trials, acoltremon 0.003% ophthalmic solution demonstrated effectiveness in increasing tear production. For more information about acoltremon ophthalmic solution 0.003%, visit #AlconScience #Innovation
Tweet media one
0
2
4
@SeeAlconScience
Alcon Science
18 days
Patient-reported quality of vision, visual outcomes and patient satisfaction after being implanted with Clareon® PanOptix® trifocal intraocular lenses were the subject of this recent study by Dr. Marius Scheepers | See the full video:
0
1
3
@SeeAlconScience
Alcon Science
19 days
In a study conducted by #Alcon under real-world conditions, Rho-kinase inhibitor netarsudil achieved meaningful reductions in intraocular pressure (IOP) and demonstrated manageable tolerability in patients with #glaucoma or ocular hypertension. Learn more in the video below.
0
1
3
@SeeAlconScience
Alcon Science
19 days
Access trusted science at your fingertips. The #AlconScience Eyetube Portal features educational videos and clinical insights from top researchers and clinicians. #Eyetube . Visit Alcon Science on Eyetube:
Tweet media one
0
1
3
@SeeAlconScience
Alcon Science
23 days
Study summary: For patients with open-angle #glaucoma or ocular hypertension, netarsudil monotherapy improved intraocular pressure thresholds compared to baseline by 8-12% across all subgroups after 12 weeks. Learn more in the video below by #Alcon:
0
2
2
@SeeAlconScience
Alcon Science
24 days
Are cataract patients with presbyopia satisfied with Clareon® PanOptix® trifocal intraocular lenses (IOLs) 3 months after cataract surgery? Dr. Marius Scheepers recently conducted a study to find out. See the full video here: #Ophthalmology #Alcon
0
1
2
@SeeAlconScience
Alcon Science
24 days
In this video, #Alcon Global Medical Affairs outlines a study of the efficacy of a Rho-kinase inhibitor for lowering intraocular pressure (IOP) in patients with #glaucoma or ocular hypertension. See how it performs as a monotherapy as well as with other IOP-lowering agents
0
1
3